A biopsy score of 3+3 sits at the very bottom of the aggressiveness scale, and most men who receive this result can expect an excellent long-term prognosis. The grade reflects tumor cells that still form recognizable, individual glands under the microscope, a pattern linked to slow growth and minimal risk of spread. That single number carries weight, because hearing the word cancer alongside any score triggers anxiety, even when the biology itself is reassuring.
Below you will find how the score is calculated, what the newer grading system calls it, and why most men with this result can safely choose monitoring over immediate treatment.
The Gleason Grading System and Where 3+3 Fits
Pathologists developed the Gleason scoring system in the 1960s to grade prostate tissue based on how tumor cells arrange themselves. Donald Gleason, a pathologist at the Minneapolis Veterans Affairs Medical Center, created the framework after observing that gland architecture, rather than cell shape alone, predicted how prostate cancers behaved. The system remains the backbone of how aggressiveness is communicated today, more than sixty years later.
How the Two Numbers Are Assigned
During a prostate biopsy, a thin needle removes tiny cores of tissue for examination. A pathologist then assigns two pattern numbers from 1 to 5, where 1 looks closest to normal tissue and 5 looks the most chaotic. The first number describes the most common pattern seen, and the second describes the next most common, and the two numbers are added together to produce a Gleason score.
Pattern 3 describes well-formed, individual glands that still look recognizably like normal prostate tissue. Pattern 4 describes fused glands, cribriform structures (glands with holes punched in the middle), or poorly defined gland formations. Pattern 5 describes sheets of tumor cells with no recognizable gland structure at all, a pattern associated with the most aggressive disease.
What the Total Score Means
The combined score runs from 6 to 10 on the conventional scale. A Gleason 6 is the lowest possible result, and every step upward reflects more disorganized tissue and greater biologic risk. Gleason 7 signals at least some pattern 4 cells, Gleason 8 signals substantial pattern 4 or some pattern 5, and Gleason 9 or 10 indicates predominantly pattern 5 disease with the highest metastatic potential.
| Gleason Score | Pattern Combination | Risk Implication |
|---|---|---|
| 6 | 3 + 3 | Lowest aggressiveness; well-formed glands only |
| 7 | 3 + 4 or 4 + 3 | Intermediate risk; pattern 4 present |
| 8 | 4 + 4, 3 + 5, or 5 + 3 | High risk; pattern 5 emerging |
| 9 or 10 | 4 + 5, 5 + 4, or 5 + 5 | Highest risk; aggressive biology |
Why Pathologists Now Prefer the ISUP Grade Group System
Pathologists found that the term “Gleason 6” caused confusion because patients heard the word cancer alongside a number that sounded low but felt like a score on a 10-point scale. In response, the International Society of Urological Pathology introduced a new grading system in 2014. The goal was to group cancers by actual prognosis rather than by a number that sounded like a midterm grade.
How Grade Groups Map to Gleason Scores
ISUP Grade Group 1 corresponds directly to Gleason 3+3=6. Grade Group 2 maps to Gleason 3+4=7, Grade Group 3 to Gleason 4+3=7, Grade Group 4 to Gleason 8, and Grade Group 5 to Gleason 9 or 10. This mapping makes risk conversations simpler because each group corresponds to a defined prognosis category, not a range of behavior.
| ISUP Grade Group | Gleason Score | Risk Category |
|---|---|---|
| 1 | 3 + 3 = 6 | Low risk |
| 2 | 3 + 4 = 7 | Favorable intermediate risk |
| 3 | 4 + 3 = 7 | Unfavorable intermediate risk |
| 4 | 8 | High risk |
| 5 | 9 or 10 | Very high risk |
Most modern pathology reports include both the Gleason score and the Grade Group, which lets clinicians compare old studies with new classifications. The American Urological Association and the National Comprehensive Cancer Network both reference Grade Groups in their current guidelines, a practice that has spread quickly across the United States.
The Real Risk Profile of a Gleason 6 Diagnosis
Tumors graded as Gleason 6 grow slowly, rarely invade surrounding structures, and have a very low likelihood of reaching distant organs. Long-term studies from major academic centers place 15-year prostate cancer-specific mortality for Gleason 6 on active surveillance below 1 percent when patients are carefully selected. That figure rivals the risk of dying from many common, non-cancer causes in the same age group.
Cases initially called Gleason 6 that later behave aggressively almost always reflect upgraded biopsy sampling rather than true pattern 3 biology, a distinction worth understanding before assuming the worst.
What Determines “Low Risk”
Three clinical measures,Gleason score, PSA level, and tumor stage,together identify a low-risk category with excellent outcomes. PSA density (PSA level divided by prostate volume) below 0.15 ng/mL per cubic centimeter, fewer than one-third of biopsy cores containing cancer, and no core showing more than 50 percent involvement all support the low-risk classification. MRI findings showing no suspicious lesions outside the biopsy area add further confidence.
When all of these factors line up, the prognosis is strong enough that many men will outlive their prostate cancer rather than die from it. This is the foundation of why active surveillance became the preferred strategy for most men with Gleason 6 disease.
Active Surveillance as the Standard Approach
Active surveillance means deferring immediate treatment while monitoring the cancer with scheduled PSA tests, imaging, and repeat biopsies. The goal is to avoid the sexual, urinary, and bowel side effects linked to surgery or radiation without measurably raising mortality risk in men whose tumor biology is favorable.
What Surveillance Involves
A typical surveillance protocol includes a PSA blood test every six months, a digital rectal exam annually, and a repeat MRI or biopsy every one to three years. The Urology Care Foundation describes surveillance as appropriate for men with low-risk disease and a life expectancy under 20 years, though many clinicians extend this approach to men with longer life expectancy when other factors support it.
Transition to active treatment is triggered only if the cancer shows higher volume, a higher Gleason pattern on repeat biopsy, or rapid PSA progression. None of those triggers means the cancer has escaped, only that the initial picture has changed enough to justify intervention.
Who Benefits Most
Men with Gleason 6 cancer, a PSA below 10 ng/mL, and a clinical stage of T1c or T2a typically meet criteria for low-risk disease and surveillance. Older men with significant other health conditions gain the most, because the side effects of treatment often arrive before the cancer ever would have caused harm. Younger men sometimes opt for treatment to avoid decades of monitoring, and that tradeoff is reasonable when fully informed.
When Gleason 7 Enters the Picture
The presence of any pattern 4 changes the conversation from observation toward discussing surgery, radiation, or combined modality therapy. Gleason 3+4=7 is classified as favorable intermediate risk, and Gleason 4+3=7 is classified as unfavorable intermediate risk within the same total score. The distinction matters because the proportion of pattern 4 influences prognosis more than the total number alone.
| Score | Pattern Breakdown | Risk Category | Typical Approach |
|---|---|---|---|
| 3 + 3 = 6 | Pattern 3 only | Low | Active surveillance |
| 3 + 4 = 7 | Mostly 3, some 4 | Favorable intermediate | Surveillance or treatment, case-by-case |
| 4 + 3 = 7 | Mostly 4, some 3 | Unfavorable intermediate | Treatment usually recommended |
Why the One-Point Gap Matters So Much
Treatment selection between Gleason 6 and Gleason 7 often differs more than the one-point gap on paper would suggest. Intermediate-risk disease carries a meaningfully higher chance of progression than Gleason 6, even when the lower number remains 3. A tumor with any pattern 4 component has demonstrated an ability to break away from normal gland architecture, and that capacity often correlates with faster growth and a higher likelihood of capsular penetration.
For this reason, the appearance of even a small amount of pattern 4 on a biopsy report typically prompts a different conversation. Options include radical prostatectomy, external beam radiation with or without hormone therapy, or in some cases a combination approach. The choice depends heavily on age, overall health, and personal priorities around quality of life.
Practical Steps After Receiving a Gleason 6 Result
A diagnosis of Gleason 6 prostate cancer often arrives with more paperwork than clarity. The biopsy report uses technical terms, and the recommendation from your urologist may feel rushed. Taking a few specific actions in the weeks after diagnosis can sharpen the picture and protect you from making a decision based on incomplete information.
Confirm the Full Picture
- Request the full pathology report. Confirm both the Gleason score and the ISUP Grade Group appear on the document, since the Grade Group framing helps clarify risk.
- Review PSA density. Ask your urologist to calculate PSA divided by prostate volume, a number below 0.15 supports low-risk classification.
- Check biopsy core details. Note how many cores contained cancer and what percentage of each positive core was involved, since these numbers influence prognosis.
- Ask about MRI findings. Multiparametric MRI results showing no lesions outside the biopsy area strengthen the case for surveillance.
Build a Second Opinion
Request a second-opinion review of the biopsy slides at a center specializing in prostate pathology whenever the diagnosis will shape major treatment decisions. Expert pathologists reclassify roughly 1 to 3 percent of biopsy cases after review, occasionally upgrading pattern 3 to pattern 4 or downgrading borderline findings. A change of even one pattern number can shift the entire management conversation.
Match the Decision to Your Priorities
Weigh personal priorities around quality of life, long-term side effects, and tolerance for monitoring before choosing between surveillance and treatment. Surgery and radiation both carry meaningful risks of urinary incontinence, erectile dysfunction, and bowel changes. Surveillance carries different tradeoffs, primarily the psychological weight of living with an untreated cancer and the discipline of repeated testing.
Neither choice is objectively better for every man with Gleason 6 disease. The right answer depends on how you balance the small risk of future progression against the certain side effects of immediate treatment.
The Bottom Line
A Gleason 3+3=6 result represents the least aggressive form of prostate cancer, with long-term mortality risk under 1 percent in well-selected patients. The newer Grade Group system reframes this diagnosis as ISUP Grade Group 1, a label designed to reduce the alarm that the word cancer naturally triggers. Most men in this category can safely choose active surveillance, reserving treatment for the small minority whose disease shows signs of progression on follow-up testing.
FAQ
Is Gleason 3+3 considered cancer?
Pathologists technically label 3+3 disease as prostate adenocarcinoma, yet many specialists describe it as an indolent malignancy that grows slowly and almost never spreads. The diagnosis is real, but the prognosis is among the most favorable of any cancer type.
What is the life expectancy with Gleason 6 prostate cancer?
Long-term studies of carefully selected men on active surveillance show prostate cancer-specific mortality below 1 percent at 15 years. Most die of other causes rather than the cancer itself.
Can Gleason 6 prostate cancer spread?
Metastatic spread to bone or distant organs occurs rarely in true 3+3 tumors, which exhibit very low potential to disseminate beyond the prostate. Cases that do spread usually reflect upgraded sampling that missed a higher-grade area on the original biopsy.
Do you need treatment for Gleason 6 prostate cancer?
Most guidelines recommend active surveillance rather than immediate treatment for Gleason 6 disease, especially when PSA density, core involvement, and MRI findings all support low-risk classification. Treatment is reserved for cases showing progression on follow-up.
How serious is a Gleason score of 6?
Six represents the lowest possible result on the conventional Gleason scale, placing the cancer in a low-risk category with excellent long-term outcomes. The seriousness lies more in the word cancer than in the score itself.
What is the difference between Gleason 6 and Gleason 7?
Pattern 3 cells dominate 3+3 tumors, while a score of 7 always contains some pattern 4 cells with more disorganized glands linked to faster growth and higher metastatic potential. This single pattern difference changes the typical management approach from surveillance to active treatment.
